Chiasma Announces 48-Week Safety and Efficacy Data from the Open-Label Extension Study of its CHIASMA OPTIMAL Phase 3 Trial Evaluating MYCAPSSA® in Patients with Acromegaly

Brenda Snow
Authentic Patient Voice

Matthew Durham
Omnidynamic Marketing

Amy Giles
Increasing Engagement

Frank Burrell
Scientific Storytelling

David Linetsky
Point-of-Care Marketing

Suma Ramadas, PhD
Medical Affairs

Daniel Sontupe
Market Access

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

Bud Bilanich
Success Coach

Joey Cohen
Medication Adherence

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment